- About
- Projects
- Column 1
- Animal Health & Veterinary Medicine
- Expanded Access
- FDA Patient Listening Sessions
- Food & Nutrition
- Column 2
- Column 1
- News and Events
- Expanded Access eRequest
Therapeutics/Vaccines Lab Meeting
Beyond the learning acceleration of our COVID-19 Evidence Accelerator lab meetings, the Evidence Accelerator model includes “engines” of evidence generation. At the June 16th Therapeutics and Vaccines meeting, we’ll review the results and performance of one of those engines, and help jump-start a new engine.
Diagnostics Lab Meeting
Join the COVID-19 Diagnostics Evidence Accelerator to check-up on what’s happening with the Mayo Clinic. Since Mayo’s (and their research partners at Yale University) participation in our research project looking at use patterns and performance of serological tests, they have continued to track and evaluate use of COVID-19 tests within their health system. We’ll learn how testing patterns have changed, and what information they have gathered (and generated) regarding test performance.
Alzheimer’s Evidence Accelerator Modeled On FDA COVID Project Floated By USAgainstAlzheimer’s - Pink Sheet
Patient organization exploring development of a multi-stakeholder forum on real world evidence that, among other things, could address research questions posed by the Centers for Medicare and Medicaid Services in its national coverage determination for Alzheimer’s drugs. Read more here.
Tracking and Monitoring of Antimicrobial Use in Food-Producing Animals
Exploring the Potential for a Public-Private Partnership to Support the Tracking and Monitoring of Antimicrobial Use in Food-Producing Animals
Virtual Public Forum
Tuesday, June 14, 2022
1-3pm Eastern Time
2022 Annual Public Meeting
More than 200 patient, consumer, industry, research, and government stakeholders joined the Foundation’s Annual Public Meeting of our Board of Directors on May 16, 2022. The event featured candid discussions with senior FDA leadership on topics ranging from data interoperability, food safety, and FDA’s plans for a return to in-person events. See highlights from the meeting below.
Woodcock Weighs in on ARPA-H - POLITICO's Prescription Pulse
If the proposed Advanced Research Projects Agency for Health is created, new treatment candidates would need to engage with FDA early on to help determine appropriate clinical testing design, FDA principal deputy commissioner Janet Woodcock said Monday at the Reagan Udall Foundation for the FDA’s annual public board of directors meeting. Read more here.
Therapeutics/Vaccines Lab Meeting
This month we will learn more about the opportunity to ‘listen’ for safety signals in social media from the Sanofi Digital team, as they share some of their advanced analytics and visualization regarding what is being said about COVID vaccine safety, with a particular focus on children.